
News|Articles|September 1, 2026
5 Essential Capabilities for Decentralized Clinical Trials
Author(s)Quest Diagnostics
Advertisement
As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report
2
Eli Lilly to Acquire Merida Biosciences for $2.8 Billion
3
BioNTech Terminates Phase II Clinical Trial for Cevumeran
4
Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences
5




